BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Pakvisal N, Goldberg RM, Sathitruangsak C, Silaphong W, Faengmon S, Teeyapun N, Teerapakpinyo C, Tanasanvimon S. Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable, RAS/BRAF wild-type, left-sided metastatic colorectal cancer. World J Clin Oncol 2025; 16(3): 102076 [PMID: 40130051 DOI: 10.5306/wjco.v16.i3.102076]
URL: https://www.wjgnet.com/2218-4333/full/v16/i3/102076.htm
Number Citing Articles
1
Simay ÇOKGEZER, Esma Nur SAĞLAM, İrem Sena BAYRAK, Muhammet ŞENKAL, Hamza Uğur BOZBEY, Didem TAŞTEKİN, Senem KARABULUT. Comparative Efficacy of Second-line Anti-VEGF Continuation and Anti-EGFR Switch Strategies in RAS Wild-type Metastatic Colorectal Cancer Patients Progressing on First-line Anti-VEGF Therapy: A Retrospective Single-center Study. Journal of Oncological Sciences 2026;  doi: 10.37047/jos.galenos.2026.2026-6-8